Table 2.

Dose-escalation schemes

	Dose-escalation schemes
	Dose level, mg q.i.d.	Patients, n	Number of days on treatmenta, range	Number of patients with DLT in cycle 1
Study 1: weekly dosing	10	3	36–106	0
	20	3	51–106	0
	40	4	8–58	0
	60	6	1–141	0
	90	3	50–106	0
Study 2: 14 days continuous dosing, 1 week rest	5	3	55–77	0
	10	3	55–98	0
	20	3	55–119	0
	40	8	5–161	2 (G2 nausea and vomiting; G5 acute renal failure)
Study 3: continuous dosing	2.5	3	35–56	0
	5	3	29–56	0
	10	5	19–87	0
	20	11	1–226	0
	40	6	3–56	2 (fatal pericarditis; G3 fatigue)

^aPeriod from first to last dose of AZD5438 treatment.

DLT, dose-limiting toxicity.